Behavioral and Psychological Symptoms of Dementia: Update on Treatments, Mechanisms and Management in the Clinic and Community


Date of CE Release: 04/01/2021

Date of CE Expiration: 04/01/2022

Learner Notification

 

Faculty:

Martin Steinberg, MD

Johns Hopkins University School of Medicine


Paul Rosenberg, MD

Johns Hopkins University School of Medicine


Deirdre Johnston, MD, Bch BAO

Johns Hopkins University School of Medicine


Brent Forester, MD, MSc

McLean Hospital

 

Summary: Behavioral and Psychological Symptoms of Dementia (BPSD) are common and challenging, with no consistently safe or effective pharmacological or non-pharmacological treatments available.  In this symposium, current evidence will be reviewed for the use of antipsychotics, serotonin specific reuptake inhibitors and mood stabilizers, in addition to dronabinol, prazosin, dextromethorphan/quinidine, pimvanserin and ECT.  This will be followed by a discussion of possible biological mechanisms of BPSD throughout the spectrum of Alzheimer’s disease severity, which may be useful for treatment development. Focus will be on areas with the best evidence, which includes agitation and apathy in established AD, and depression, anxiety and apathy in preclinical and prodromal AD.  Other important contributing factors to BPSD include physical and social conditions, as well as the dynamic between caregivers and persons with dementia. Findings will be discussed from the MIND at Home multidisciplinary intervention, which is designed to support persons with dementia and their caregivers at home in the community.  This symposium will end with a review of evidence-based models of integrated dementia care and discussion of the experiences of developing and launching an integrated dementia care team using a collaborative care approach across Mass General Brigham, a large and diverse health care system.

 

UAN: JA4008163-9999-21-058-H04-P
Activity Type: Knowledge Based

Objectives for Webinar:

1. At the end of this session, participants should be aware of the latest evidence for the use of eight medication classes and ECT in the treatment of Behavioral and Psychological Symptoms of Dementia.

2. At the end of this session, participants should be able to identify two brain regions associated with agitation and apathy.

3. At the end of this session, participants should be able to identify four ways in which the MIND at Home multidisciplinary intervention provides support for persons with dementia and their caregivers.

4. At the end of this session, participants should be familiar with the implementation of an evidence-based model of integrated dementia care across a health care system that places an emphasis on quality and reducing health care costs.

 

Acknowledgement of Support
This webinar is supported in part by an unrestricted educational grant provided by the American Board of Psychiatry and Neurology (ABPN).

 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians

Amedco LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

Nurses

Amedco LLC designates this activity for a maximum of1.0 ANCC contact hours.

 

Pharmacists

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

 

Psychologists

Amedco LLC designates this activity for a maximum of 1.0 psychologist contact hours. 

 

Click here for list of state boards accept courses from APA providers for Counselors, MFTs, Addictions Professionals, and Social Workers.

 

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 1.0 GENERAL continuing education credits.

 

Click here for list of state boards accept courses offering ASWB ACE credit for Social Workers, Counselors, MFTs, and Addictions Professionals.

 

Disclosure of Relevant Financial Relationships:

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

 

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships.

 

Martin Steinberg

No relevant financial relationship exists

Paul Rosenberg Cerevel - consultant

Acadia - consultant

Bioxcel - consultant
Deirdre Johnston MIND at Home Newco – Founder

Translation partnership with healthcare organization subject to NDA

Brent Forester

Acadia Pharmaceuticals – Consultant

Eli Lilly - Research Grant Site Principal Investigator

Biogen - Research Grant Site Principal Investigator; Consultant

Eisai - Research Grant Site Principal Investigator

 

 

Click here to complete the Webinar Post Test and CE Evaluation 

 

Back to webinar listing